Antibiotic Prophylaxis in Rhinoplasty

• Status: Enrolling by invitation
• Trial end date: 2024-04-20
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborators: Duke University; Harvard University; Université de Montréal; University of Kansas Medical Center; University of Washington; Vanderbilt University School of Medicine; Washington University School of Medicine
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cephalexin; Clindamycin; Clindamycin palmitate; Clindamycin phosphate

Criteria

Inclusion Criteria:

Adult patients (aged 18years and older)

Exclusion Criteria:

• Prior rhinoplasty

• Any exogenous (non-nasal) grafts/implants

• Immune deficiency (DM, meds, other)

• History of radiotherapy to nose